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Abstract Mitochondrial intermembrane proteins including cy-
tochrome c are known to activate caspases. Accordingly, a
disruption of the mitochondrial membrane barrier function with
release of cytochrome into the cytosol has been shown to precede
caspase activation in a number of different models of apoptosis.
Here, we addressed the question of whether caspases themselves
can affect mitochondrial membrane function. Recombinant
caspases were added to purified mitochondria and were found
to affect the permeability of both mitochondrial membranes.
Thus, caspases cause a dissipation of the mitochondrial inner
transmembrane potential. In addition, caspases cause intermem-
brane proteins including cytochrome c and AIF (apoptosis-
inducing factor) to be released through the outer mitochondrial
membrane. These observations suggest that caspases and
mitochondria can engage in a circular self-amplification loop.
An increase in mitochondrial membrane permeability would
cause the release of caspase activators, and caspases, once
activated, would in turn increase the mitochondrial membrane
permeability. Such a self-amplifying system could accelerate the
apoptotic process and/or coordinate the apoptotic response
between different mitochondria within the same cell.
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1. Introduction
In most models of apoptosis, the permeability of the inner
and/or outer mitochondrial membranes increases early during
the death process leading to the dissipation of the inner trans-
membrane potential (v8m) and/or the release of intermem-
brane proteins into the cytosol [1,2]. The exact chronological
and cause-e¡ect relationship between the increase in inner
versus outer mitochondrial membrane permeability is not
understood and may depend on the cell type and/or apoptosis
inducer [3^11]. In many cases, opening of the mitochondrial
megachannel (or permeability transition pore) appears to be
critical for the apoptotic process because inhibition of mega-
channel opening prevents cell death [1,12^15]. Opening of the
megachannel in isolated mitochondria causes several changes
in mitochondria which are also found in apoptosis: v8m dis-
sipation, matrix swelling, and rupture of the outer mitochon-
drial membrane resulting in the release of intermembrane pro-
teins [1,9,11,16^19]. Opening of the megachannel is controlled
by the apoptosis inhibitory proteins Bcl-2 and Bcl-XL
[12,20,21].
Several mitochondrial intermembrane proteins have been
shown to activate caspases, a class of proteases whose activa-
tion is indispensable for the acquisition of apoptotic morphol-
ogy [22]. Thus, the 15 kDa protein cytochrome c can interact
with the ATP-binding protein Apaf-1 to form a complex
which proteolytically activates pro-caspase 9 (or favors its
autoactivation) [23,24]. Another intermembrane protein, the
V50 kDa AIF (apoptosis-inducing factor), also may have a
caspase-activating potential [8]. In contrast to cytochrome c
and caspases, AIF su⁄ces to activate nuclear endonucleases in
the absence of further cytosolic proteins [6]. While cyto-
chrome c and caspases act via a caspase-activated DNase,
also called DNA fragmentation factor (DFF) [25], addition
of puri¢ed AIF itself can provoke nuclear apoptosis in vitro
[6]. In accord with its putative role in caspase activation,
pharmacological inhibition of the megachannel can prevent
the activation of caspases [14,26]. Moreover, Bcl-2 and Bcl-
XL, which inhibit the megachannel [12,20,21] and favor the
retention of intermembrane proteins in mitochondria [4^8],
inhibit the activation of downstream caspases [27,28].
Altogether, it appears that the disruption of mitochondrial
membrane function occurs mostly upstream of caspase acti-
vation [8,26]. Nonetheless, in some models of apoptosis, cas-
pase activation is an early feature of signal transduction.
Thus, crosslinking or ligation of CD95/Fas/APO-1 has been
shown to cause the recruitment of pro-caspase 8 into a recep-
tor complex [29,30], thereby stimulating the primary (that is
pre-mitochondrial) activation of caspases [8,28]. In CD95/Fas/
APO-1-induced apoptosis, inhibition of this ‘upstream cas-
pase’ by transfection with the selective caspase inhibitor
crmA or synthetic peptides prevents the mitochondrial mani-
festations of apoptosis [8,31,32], underlining that they do in-
deed function upstream of mitochondria. Stimulated by these
¢ndings, we decided to evaluate the e¡ects of caspases on
isolated mitochondria in vitro. Here, we show that a number
of di¡erent recombinant caspases can act on mitochondria to
disrupt their membrane barrier function.
2. Materials and methods
2.1. Materials
Recombinant caspases produced as active enzymes as previously
described [33,34] were kindly provided by Nancy Thornberry (Merck,
Rahway, NJ, USA) or by Guy Salvesen (Burnham Institute, La Jolla,
CA, USA). Caspase activity is de¢ned as the amount of enzyme re-
quired to cleave 1 Wmol of the £uorogenic substrate Ac-DEVD-amc
(caspase 2, 3, 6, 7, 8), Ac-YVAD-amc (caspase 1), or Ac-WEHD.amc
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(caspase 4, 5) per hour. All caspase substrates and inhibitors (Ac-
DEVD.cmk, Ac-YVAD.cmk, Z-VAD.fmk) were purchased from
Bachem (Basel, Switzerland). All remaining reagents were from Sigma
(St. Louis, MO), unless speci¢ed di¡erently. Mitochondria from
mouse liver were puri¢ed on a Percoll (Pharmacia, Uppsala, Sweden)
gradient, following published protocols [35].
2.2. Determination of cytochrome c release
Isolated mitochondria (1 mg mitochondrial protein per ml; 50 Wl/
tube) were incubated in a bu¡er containing (400 mM mannitol;
50 mM Tris-HCl; 0.5% (w/v) bovine serum albumin; 10 mM
KH2PO4 ; pH 7.2) in the presence of 0.1^1 U recombinant caspases
for 30 min at room temperature. Thereafter, mitochondria were spun
down (12 000Ug, 3 min, 4‡C). Aliquots of the supernatant (10 Wl)
were subjected to PAGE gel electrophoresis (12%), Western blot on
nitrocellulose, and immunodetection of cytochrome c using a speci¢c
monoclonal antibody (clone 7H8.2C12, Pharmingen), as described
[23].
2.3. Oxygen uptake and membrane potential
Membrane potential and oxygen uptake were simultaneously meas-
ured in an oxygen-electrode chamber (Hansatech, UK) using tetra-
phenylphosphonium cation (TPP) as a membrane potential probe.
The transmembrane potential (v8m) was measured at 25‡C in a ¢nal
volume of 1.5 ml respiratory medium consisting of 0.3 M sucrose,
10 mM KCl, 5 mM MgCl2, 10 mM TES, 10 mM KH2PO4 (pH
7.2). The TPP binding was corrected according to Hashimoto and
Rottenberg [36].
2.4. Determination of AIF release
Mitochondria were resuspended in cell-free system (CFS) bu¡er
(220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM KH2PO4,
0.5 mM EGTA, 2 mM MgCl2, 5 mM pyruvate, 0.1 mM phenylmeth-
ylsulfonyl £uoride (PMSF), 1 mM dithiothreitol, 10 mM HEPES-
NaOH, pH 7.2) in the presence or absence of recombinant caspase
and caspase inhibitors (100 WM Ac-DEVD.cmk or Ac-YVAD.cmk)
for 15 min, followed by centrifugation as above (12 000Ug, 3 min,
4‡C). The supernatant was subject to a second centrifugation
(150 000Ug, 30 min, 4‡C) to remove particles. Nuclei from HeLa or
2B411 T cell hybridoma cells puri¢ed on a sucrose gradient [37] were
cultured at a density of 103 nuclei/Wl in the presence of mitochondrial
supernatants for 90 min at 37‡C in CFS bu¡er. Alternatively, puri¢ed
cytochrome c from bovine heart (Sigma) was added. Without prior
¢xation, nuclei were stained with propidium iodide (PI) (10 Wg/ml;
Sigma; v 5 min at room temperature), followed by cyto£uorometric
analysis in a EPICS Pro¢le II Analyzer (Coulter, Hialeah, FL), while
gating the forward and side scatters on single-nucleus events [38].
3. Results and discussion
3.1. Recombinant caspases cause cytochrome c release from
isolated mitochondria
As cytochrome c release is a critical event in several in vitro
models of apoptosis [5,7,23,24], we have evaluated the ca-
pacity of caspases to provoke release of this protein, which
is normally con¢ned to the mitochondrial intermembrane
space. Mitochondria were incubated with recombinant, enzy-
matically active caspases, followed by immunodetection of
cytochrome c release into the supernatant. As demonstrated
in Fig. 1, all tested caspases (1, 2, 5, 6, 7, 8, 9) did indeed
cause the liberation of cytochrome c from the mitochondrial
intermembrane space.
3.2. Caspases cause the release of AIF from isolated
mitochondria
AIF is biologically de¢ned as an activity that causes DNA
fragmentation in isolated nuclei in vitro [6,38]. As shown in
Fig. 2, the supernatant of mitochondria with the megachan-
nel-opening agent atractyloside (but not the supernatant of
control mitochondria) contains an activity which provokes
loss of DNA in isolated HeLa nuclei, as quanti¢ed by staining
with the DNA-intercalating dye PI and cyto£uorometry. In
contrast, puri¢ed cytochrome c did not a¡ect the DNA con-
tent of isolated HeLa nuclei, thus con¢rming the assertion
that AIF is not identical with cytochrome c [6,8]. Incubation
of mitochondria with recombinant caspases causes the release
of an AIF activity. In this experimental system, recombinant
caspases (1, 2, 4, 6, 8) added in the absence of mitochondria
have no e¡ect on the DNA content of puri¢ed nuclei (not
shown). Inhibition of their activity, after recovery of the mi-
tochondrial supernatant, using speci¢c tetrapeptide inhibitors
does not abolish the AIF activity contained in the mito-
chondrial supernatant. Thus, in conditions in which Ac-
YVAD.cmk or Ac-DEVD.cmk fully prevent the caspase-
mediated cleavage of the £uorogenic substrates Ac-YVAD.afc
or Ac-DEVD.afc (not shown), the AIF activity recovered in
the supernatant remains active (Fig. 2). AIF activity is only
a¡ected by the tripeptide inhibitor Z-VAD.fmk, which results
in its partial inhibition, as previously described [6]. These data
indicate that caspases, though themselves inactive on isolated
nuclei, can provoke the release of AIF from mitochondria.
3.3. Recombinant caspases disrupt the v8m
Since caspases cause the release of cytochrome c and AIF
through the outer mitochondrial membrane, we determined
their e¡ect on the inner transmembrane electrochemical gra-
dient. Mitochondria treated with recombinant caspases were
resuspended in a bu¡er containing succinate and rotenone,
followed by determination of the v8m with a TPP-sensitive
electrode. As shown in Fig. 3, caspases do indeed provoke a
reduction of the v8m, and this e¡ect is inhibited by pre-in-
cubation of caspases with an excess of tetrapeptide inhibitors.
Pre-incubation of mitochondria with a low dose of recombi-
nant caspase 1 gradually increases the sensitivity of mitochon-
dria to Ca2-induced permanent disruption of the v8m, which
is a sign of mitochondrial permeability transition. Thus, un-
treated mouse liver mitochondria require 5 additions of
75 nmol Ca2 (per mg protein) to induce for durable v8m
dissipation ([11] and Fig. 4A). In contrast, mitochondria pre-
treated with caspase 1 during 10 min only required 2 additions
of 75 nmol Ca2 to obtain the same e¡ect (Fig. 2C). After
30 min of pre-incubation, caspase 1 itself su⁄ced to cause a
permanent disruption of the v8m (Fig. 2D). Addition of
exogenous cytochrome c after antimycin A (which inhibits
the respiratory complex II) failed to enhance oxygen con-
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Fig. 1. Recombinant caspases cause cytochrome c release from iso-
lated mitochondria. Mitochondria were incubated in the presence or
absence of di¡erent recombinant caspases (20 U/ml), as described in
Section 2, followed by centrifugation and recovery of the superna-
tant. The supernatants were then subjected to SDS-PAGE, Western
blot and immunodetection of cytochrome c using a speci¢c mono-
clonal antibody. Incubation with atractyloside (5 mM) served as an
internal control of maximum cytochrome c release. The immunode-
tection yielded one single band corresponding to a molecular weight
of 15 kDa.
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sumption by untreated control mitochondria (insert in Fig.
1A), although it did so in mitochondria treated with caspase
1 and/or calcium to achieve a permanent v8m dissipation
(Fig. 4B^D). This indicates that the outer mitochondrial mem-
brane has become permeable to exogenous cytochrome c after
Ca2 and/or caspase 1 have acted on mitochondria. Analo-
gous results were obtained when caspase 3 instead of caspase
1 was used (not shown). Of note, it appeared that cytochrome
c did not restore the v8m in conditions in which it increased
the oxygen consumption of mitochondria, suggesting that mi-
tochondria are durably uncoupled after caspase treatment
(Fig. 4D).
3.4. Concluding remarks
In this work we show that several di¡erent recombinant
caspases share the capacity to perturb the mitochondrial
membrane barrier function, at the levels of both the outer
and the inner mitochondrial membranes. Thus, the outer
membrane becomes permeable to the intermembrane proteins
cytochrome c and AIF (Figs. 1, 2 and 4). Furthermore, the
proton gradient normally built up on the inner membrane
dissipates upon incubation with caspases (Figs. 3 and 4). In
the experimental conditions described in this paper, it appears
that loss of barrier function of the inner and the outer mem-
branes occur in a quasi-simultaneous fashion (Figs. 1^4 and
data not shown). The membrane-permeabilizing e¡ect of cas-
pases is probably due to e¡ects on speci¢c protein substrates
in the mitochondrial membranes, based on the observation
that neutralization of caspase proteolytic activity with tetra-
peptide inhibitors abolished their e¡ects on mitochondria
(Fig. 3). Moreover, we have previously shown that caspases
can increase the membrane permeability of proteoliposomes
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Fig. 2. Recombinant caspases cause the release of AIF from isolated mitochondria. Mitochondria were incubated in the absence (control) or in
the presence of atractyloside (5 mM, 30 min) or the indicated caspase (20 U/ml), followed by centrifugation and recovery of the supernatant.
The supernatants were pre-incubated during 10 min in the presence or absence of Ac-YVAD.cmk, Ac-DEVD.cmk and/or Z-VAD.fmk
(100 WM), as indicated, before they were added to puri¢ed HeLa cell nuclei. Nuclei and mitochondrial supernatants were cultured during
90 min at 37‡C, followed by determination of the DNA content by staining with PI and cyto£uorometric analysis. Results are also shown for
nuclei kept in the presence of 100 Wg/ml cytochrome c.
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containing mitochondrial proteins, whereas they have no ef-
fects on protein-free liposomes [20]. The nature of the caspase
substrates contained in the mitochondrial membrane, how-
ever, remains to be clari¢ed. As a possibility, proteins of the
Bcl-2 family may be the target of caspases. Thus, Bcl-2 is a
caspase 3 substrate, and Bcl-XL is a caspase 1 substrate
[39,40]. However, liver mitochondria contain little if any
Bcl-2 [41], suggesting that caspase 3 and its homologues
must act on other proteins.
As outlined in Section 1, proteins which are normally se-
cluded by the mitochondrial outer membrane can act as po-
tent caspase activators when they are released into the cytosol
[5,7,8,23,24]. Although data obtained in several cell-free sys-
tems of apoptosis induction would suggest that caspase acti-
vation usually occurs downstream of mitochondrial mem-
brane permeabilization [5,7,8,23,24], the data presented here
indicate that caspases can also act upstream of mitochondria.
It is certainly conceivable that mitochondria and caspases
engage in a circular ampli¢cation loop of mutual activation,
thereby locking the cell in an irreversible stage of death com-
mitment. We have previously observed that during apoptosis
di¡erent mitochondria located in the same cell lose their v8m
in a quasi-simultaneous fashion [42], suggesting that some sort
of inter-mitochondrial coordination exists. An ampli¢cation
loop between caspases and mitochondria might ful¢ll such a
coordinating function.
When integrating the data from this study and from pre-
ceding papers, it is tempting to envisage a scenario in which
the disruption of mitochondrial barrier function determines
the decision between survival and death, whereas the activa-
tion of downstream caspases, which is necessary for the ac-
quisition of apoptotic morphology, would determine the
modality of death (necrosis versus apoptosis). Normally,
disruption of mitochondrial barrier function and caspase ac-
tivation would be tied together by mutually stimulatory e¡ects
of caspases and mitochondria. Only in circumstances in which
caspase activation is blocked (e.g. by cysteine oxidation or
nitrosylation, ATP depletion, or synthetic inhibitors such as
Z-VAD.fmk), the primary disruption of mitochondrial barrier
function would fail to activate the apoptotic default death
pathway and instead provoke a non-apoptotic, cytolytic
type of cell death. This scenario is compatible with most of
the published data [26,43^47] and would allow for the oper-
ative reinterpretation of the sometimes spurious di¡erence be-
tween necrotic and apoptotic cell death.
In conclusion, the observation that caspases can perturb the
mitochondrial membrane barrier function has far-reaching
implications for our understanding of apoptotic signaling.
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